# Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

> **NCT01931150** · PHASE3 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Cetuximab-induced Papulopustular (Acneiform) Rash Who Have
- Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Topical Dapsone 5% Gel
- **OTHER:** Moisturizer
- **DRUG:** oral antibiotics

## Key facts

- **NCT ID:** NCT01931150
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2017-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01931150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01931150, "Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01931150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*